Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Singh discuss the key role of fluid in the treatment of wet AMD, dosing interval data from clinical trials, and the importance of patient expectations when selecting therapy.